Clear Search

Showing 4 results for “Wilding JPH”.

April 2023

Effects of Dapagliflozin on Hospitalisations in People with Type 2 Diabetes: Post-hoc Analyses of the DECLARE-TIMI 58 Trial

Lancet Diabetes Endocrinol. 2023;11:233–241 DOI: 10.1016/S2213-8587(23)00009-8

In patients with T2D at high risk of CV or kidney disease, SGLT2is consistently reduce the risk of HF hospitalisations. Less is known about their effects on hospitalisation from any cause, especially in patients with T2D without ASCVD, which includes most of the global population with T2D. Post hoc analyses of DECLARE-TIMI 58 assessed the effect of dapagliflozin on the risks of hospitalisations for any cause and for specific causes in patients with T2D with and without ASCVD.


December 2022

Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58

Diabetes Care. 2022; online ahead of print DOI: 10.2337/dc22-1318

Limited data exist regarding the cardiorenal efficacy and safety of SGLT2i in patients treated with intensive insulin regimens including short-acting insulin or high insulin doses. This post hoc analysis of DECLARE-TIMI 58 examined the effects of dapagliflozin vs placebo among 7,013 insulin users at baseline, of whom 4,650 were on regimens that included short-acting insulin and 1,339 were receiving insulin >1 IU/kg.


September 2022

Obesity and Effects of Dapagliflozin on Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 trial

Eur Heart J 2022;43:2958-67

In the DECLARE-TIMI 58 trial, patients with type 2 diabetes and higher body weight were more likely to have hospitalisation for heart failure (HHF) and atrial fibrillation or flutter (AF/AFL).


January 2022

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

N Engl J Med 2019;380:347–57 DOI 10.1056/NEJMoa1812389

Dapagliflozin was found to be noninferior to placebo in terms of major adverse cardiovascular events in the DECLARE-TIMI 58 trial.